| 虞嘉康,周蕾,倪纯明.大黄廑虫丸联合抗病毒治疗乙型肝炎肝硬化对凝血功能紊乱、肝硬化程度及门静脉系统相关参数的影响[J].安徽医药,2024,28(5):998-1001. |
| 大黄廑虫丸联合抗病毒治疗乙型肝炎肝硬化对凝血功能紊乱、肝硬化程度及门静脉系统相关参数的影响 |
| Effects of Dahuang Zhechong pill combined with antiviral treatment on coagulation disorders, severity of cirrhosis and portal system related parameters in patients with hepatitis B cirrhosis |
| |
| DOI：10.3969/j.issn.1009-6469.2024.05.032 |
| 中文关键词: 乙型肝炎，慢性 肝硬化 大黄廑虫丸 抗病毒治疗 凝血功能紊乱 门静脉系统 |
| 英文关键词: Hepatitis B,chronic Liver cirrhosis Dahuang Zhechong pill Antiviral treatment Coagulation disorders Portal system |
| 基金项目: |
|
| 摘要点击次数: 904 |
| 全文下载次数: 428 |
| 中文摘要: |
| 目的探讨大黄廑虫丸联合抗病毒治疗乙型肝炎(HBV)肝硬化对病人凝血功能紊乱、肝硬化程度及门静脉系统相关参数的影响。方法选择 2020年 6月至 2022年 6月于无锡市中医医院接受治疗的 100例 HBV肝硬化病人，运用随机数字表法将其分为观察组与对照组，各 50例。对照组采用常规抗病毒疗法，观察组基于对照组联合大黄廑虫丸，评估两组疗效并进行比较，对比两组凝血功能、 HBV-DNA值、肝硬化程度、门静脉系统相关参数变化。结果观察组治疗显效病人占 50.00%高于对照组 26.00%，差异有统计学意义( P<0.05)；治疗前两组病人的血小板计数( PLT)、凝血酶时间( TT)、纤维蛋白原( FIB)、 HBV-DNA水平比较差异无统计学意义(P>0.05)治疗后 PLT［(125.42±24.57)×109/L比( 116.12±21.38)×109/L］、 FIB水平［(2.76±0.56) g/L比( 1.80±0.63)g/L］高于对照组， TT［( 14.1，8±4.28)s比( 16.61±5.34)s］、 HBV-DNA［( 2.72±0.43)×105 IU/L比( 3.38±0.68)×105 IU/L］小于对照组，差异有统计学意义( P<0.05)；两组治疗前后的肝硬化程度和门静脉内径比较差异无统计学意义( P>0.05)，治疗后观察组肝脏硬度数值( LSM)(15.32±2.27)kPa比( 17.94±2.34)kPa、肝门静脉内径［(12.29±1.98)mm比( 13.80±2.15)mm］低于对照组，差异有统计学意义( P<0.05)；两组治疗前天冬氨酸氨基转移酶( AST)、丙氨酰氨基转移酶( ALT)水平比较差异无统计学意义( P>0.05)，治疗后 ALT、AST水平均下降，观察组下降幅度高于对照组，差异有统计学意义( P<0.05)。结论相较于单独抗病毒治疗，联合大黄廑虫丸治疗，疗效较好，改善肝功能，有助于凝血功能的恢复，缩小肝门静脉内径。 |
| 英文摘要: |
| Objective To investigate the effect of Dahuang Jinchong pill combined with antiviral therapy on blood coagulation disor-der, degree of liver cirrhosis and related parameters of portal vein system in patients with hepatitis B (HBV) cirrhosis.Methods One hundred patients with HBV liver cirrhosis who were treated in Wuxi Hospital of Traditional Chinese Medicine from June 2020 to June2022 were selected and randomly assigned into the observation group (n=50) and the control group (n=50). The control group was treat-ed with conventional antiviral therapy, while the observation group was treated with Dahuang Jinchong pill based on the control group.The efficacy of the two groups was evaluated and compared, and the changes of coagulation function, HBV-DNA, degree of cirrhosis, and related parameters of portal vein system between the two groups were compared. Results The effective rate of the observation group (50.00%) was significantly higher than 26.00% of the control group, and the difference was statistically significant (P<0.05). There was no significant difference in platelet count (PLT), thrombin time (TT), fibrinogen (FIB) and HBV-DNA levels between the two groups before treatment (P>0.05). After treatment, the levels of PLT [(125.42±24.57)×109/ L vs. (116.12±21.38)×109 /L] and FIB [(2.76± 0.56) g/L vs. (1.80±0.63) g/L] were significantly higher than those in the control group, while TT [(14.18±4.28) s vs. (16.61±5.34) s], HBV-DNA [(2.72±0.43)×105 IU/L vs. (3.38±0.68)×105 IU/L] were lower than those in the control group, and the differences were statisti-cally significant (P<0.05). There was no significant difference in the degree of liver cirrhosis and portal vein diameter between the twogroups before and after treatment (P>0.05). After treatment, the liver stiffness (LSM) [(15.32±2.27) kPa vs. (17.94±2.34)kPa] and portal vein diameter [(12.29±1.98) mm vs. (13.80±2.15) mm] in the observation group were significantly lower than those in the control group,and the differences were statistically significant (P<0.05). There was no significant difference in the levels of aspartate aminotransferase(AST) and alanyl aminotransferase (ALT) between the two groups before treatment (P>0.05). After treatment, the levels of ALT and ASTdecreased, and the decrease range in the observation group was significantly higher than that in the control group, and the differenceswere statistically significant (P<0.05).Conclusion Compared with the antiviral therapy alone, the combination of Dahuang Jinchong pill has a better therapeutic effect, improving the liver function, helping to restore the blood coagulation function, and reducing the di-ameter of the hepatic portal vein. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
